19KA Stock Overview
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CorMedix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.70 |
| 52 Week High | US$12.70 |
| 52 Week Low | US$2.66 |
| Beta | 1.53 |
| 1 Month Change | -17.20% |
| 3 Month Change | 4.76% |
| 1 Year Change | 142.14% |
| 3 Year Change | 86.89% |
| 5 Year Change | 31.62% |
| Change since IPO | -46.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 19KA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.9% | 2.2% | 0.7% |
| 1Y | 142.1% | -16.8% | 8.4% |
Return vs Industry: 19KA exceeded the German Pharmaceuticals industry which returned -16.2% over the past year.
Return vs Market: 19KA exceeded the German Market which returned 8.4% over the past year.
Price Volatility
| 19KA volatility | |
|---|---|
| 19KA Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 19KA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 19KA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 83 | Joe Todisco | www.cormedix.com |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
CorMedix Inc. Fundamentals Summary
| 19KA fundamental statistics | |
|---|---|
| Market cap | €478.90m |
| Earnings (TTM) | -€44.97m |
| Revenue (TTM) | €11.95m |
40.7x
P/S Ratio-10.8x
P/E RatioIs 19KA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 19KA income statement (TTM) | |
|---|---|
| Revenue | US$12.26m |
| Cost of Revenue | US$2.01m |
| Gross Profit | US$10.25m |
| Other Expenses | US$56.40m |
| Earnings | -US$46.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 83.57% |
| Net Profit Margin | -376.35% |
| Debt/Equity Ratio | 0% |
How did 19KA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 11:49 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CorMedix Inc. is covered by 18 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Edward White | FBR Capital Markets & Co. |
| Morris Ajzenman | Griffin Securities |